OBJECTIVES: This study measured and compared the pharmacokinetics of CMPD167, a small molecule antiretroviral CCR5 inhibitor with potential as an HIV microbicide, following vaginal, rectal and oral administration in rhesus macaques. METHODS: A vaginal hydroxyethylcellulose (HEC) gel, a rectal HEC gel, a silicone elastomer matrix-type vaginal ring and an oral solution, each containing CMPD167, were prepared and administered to rhesus macaques pretreated with Depo-Provera. CMPD167 concentrations in vaginal fluid, vaginal tissue (ring only), rectal fluid and blood plasma were quantified by HPLC-mass spectrometry. RESULTS: CMPD167 concentrations measured in rectal fluid, vaginal fluid and blood plasma were highly dependent on both the route of administration and the formulation type. Although rectal and vaginal fluid concentrations were highest when CMPD167 was administered locally (via either gel or ring), lower concentrations of the drug were also measured in these compartments following administration at the remote mucosal site or orally. CMPD167 levels in the vaginal and rectal fluid following oral administration were relatively low compared with local administration. CONCLUSIONS: The study provides clear evidence for vaginal-rectal and rectal-vaginal drug transfer pathways and suggests that oral pre-exposure prophylaxis with CMPD167 may be less efficacious at preventing sexual transmission of HIV-1 than topically applied products.
OBJECTIVES: This study measured and compared the pharmacokinetics of CMPD167, a small molecule antiretroviral CCR5 inhibitor with potential as an HIV microbicide, following vaginal, rectal and oral administration in rhesus macaques. METHODS: A vaginal hydroxyethylcellulose (HEC) gel, a rectal HEC gel, a silicone elastomer matrix-type vaginal ring and an oral solution, each containing CMPD167, were prepared and administered to rhesus macaques pretreated with Depo-Provera. CMPD167 concentrations in vaginal fluid, vaginal tissue (ring only), rectal fluid and blood plasma were quantified by HPLC-mass spectrometry. RESULTS:CMPD167 concentrations measured in rectal fluid, vaginal fluid and blood plasma were highly dependent on both the route of administration and the formulation type. Although rectal and vaginal fluid concentrations were highest when CMPD167 was administered locally (via either gel or ring), lower concentrations of the drug were also measured in these compartments following administration at the remote mucosal site or orally. CMPD167 levels in the vaginal and rectal fluid following oral administration were relatively low compared with local administration. CONCLUSIONS: The study provides clear evidence for vaginal-rectal and rectal-vaginal drug transfer pathways and suggests that oral pre-exposure prophylaxis with CMPD167 may be less efficacious at preventing sexual transmission of HIV-1 than topically applied products.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Ronald S Veazey; Martin S Springer; Preston A Marx; Jason Dufour; Per Johan Klasse; John P Moore Journal: Nat Med Date: 2005-11-06 Impact factor: 53.440
Authors: Claire J Forbes; Deborah Lowry; Leslie Geer; Ronald S Veazey; Robin J Shattock; Per Johan Klasse; Mark Mitchnick; Laurie Goldman; Lara A Doyle; Brendan C O Muldoon; A David Woolfson; John P Moore; R Karl Malcolm Journal: J Control Release Date: 2011-08-12 Impact factor: 9.776
Authors: Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson Journal: Vaccine Date: 2009-09-10 Impact factor: 3.641
Authors: John W McBride; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Peter Boyd; Vicky L Kett; R Karl Malcolm Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: Anna K Blakney; Yonghou Jiang; Dale Whittington; Kim A Woodrow Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2016-05-02 Impact factor: 3.205
Authors: Teresa L Parsons; Joshua F Emory; Lauren A Seserko; Wutyi S Aung; Mark A Marzinke Journal: J Pharm Biomed Anal Date: 2014-06-21 Impact factor: 3.935
Authors: Ronald S Veazey; Udayan Chatterji; Michael Bobardt; Kasi E Russell-Lodrigue; Jian Li; Xiaolei Wang; Philippe A Gallay Journal: Antimicrob Agents Chemother Date: 2015-11-09 Impact factor: 5.191